Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

Massimiliano Castellazzi; Serena Delbue; Francesca Elia; Matteo Gastaldi; Diego Franciotta; Roberta Rizzo; Tiziana Bellini; Roberto Bergamaschi; Enrico Granieri; Enrico Fainardi

doi:10.1155/2015/901312

Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

Massimiliano Castellazzi, Serena Delbue, Francesca Elia, Matteo Gastaldi, Diego Franciotta, Roberta Rizzo, Tiziana Bellini, Roberto Bergamaschi, Enrico Granieri, Enrico Fainardi

Fondazione "Istituto Neurologico Casimiro Mondino"

Research output: Contribution to journal › Article › peer-review

Abstract

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Natalizumab, a humanized anti-α4 integrin monoclonal antibody, is a highly effective treatment approved for MS. An association between MS and an exposure to Epstein-Barr Virus (EBV) sustained by the levels of antiviral capsid antigen (VCA) and anti-Epstein-Barr nuclear antigen-1 (EBNA-1) IgG has been described. Our goal was to verify the utility of EBV-specific IgG as a marker in Natalizumab treated MS. Twenty patients (17 female and 3 male) in treatment with Natalizumab were enrolled. Serum levels of anti-VCA and anti-EBNA-1 IgG were determined and expressed as arbitrary units (AU) before treatment and every three months for 21 months of therapy. Anti-VCA IgG levels were increased at the 15th month (235410 ± 196712 AU) comparing with the 3rd (98146 ± 47145 AU) and the 6th (109866 ± 52270 AU) months of therapy p

Original language	English
Article number	901312
Journal	Disease Markers
Volume	2015
DOIs	https://doi.org/10.1155/2015/901312
Publication status	Published - 2015

ASJC Scopus subject areas

Biochemistry, medical
Clinical Biochemistry
Molecular Biology
Genetics

Access to Document

10.1155/2015/901312

Fingerprint Dive into the research topics of 'Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment'. Together they form a unique fingerprint.

Cite this

Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. / Castellazzi, Massimiliano; Delbue, Serena; Elia, Francesca; Gastaldi, Matteo; Franciotta, Diego; Rizzo, Roberta; Bellini, Tiziana; Bergamaschi, Roberto; Granieri, Enrico; Fainardi, Enrico.

In: Disease Markers, Vol. 2015, 901312, 2015.

Research output: Contribution to journal › Article › peer-review

@article{b7b62fde18ce4bd3a4691c923a3df87c,

title = "Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment",

abstract = "Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Natalizumab, a humanized anti-α4 integrin monoclonal antibody, is a highly effective treatment approved for MS. An association between MS and an exposure to Epstein-Barr Virus (EBV) sustained by the levels of antiviral capsid antigen (VCA) and anti-Epstein-Barr nuclear antigen-1 (EBNA-1) IgG has been described. Our goal was to verify the utility of EBV-specific IgG as a marker in Natalizumab treated MS. Twenty patients (17 female and 3 male) in treatment with Natalizumab were enrolled. Serum levels of anti-VCA and anti-EBNA-1 IgG were determined and expressed as arbitrary units (AU) before treatment and every three months for 21 months of therapy. Anti-VCA IgG levels were increased at the 15th month (235410 ± 196712 AU) comparing with the 3rd (98146 ± 47145 AU) and the 6th (109866 ± 52270 AU) months of therapy p",

author = "Massimiliano Castellazzi and Serena Delbue and Francesca Elia and Matteo Gastaldi and Diego Franciotta and Roberta Rizzo and Tiziana Bellini and Roberto Bergamaschi and Enrico Granieri and Enrico Fainardi",

year = "2015",

doi = "10.1155/2015/901312",

language = "English",

volume = "2015",

journal = "Disease Markers",

issn = "0278-0240",

publisher = "IOS Press",

}

TY - JOUR

T1 - Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

AU - Castellazzi, Massimiliano

AU - Delbue, Serena

AU - Elia, Francesca

AU - Gastaldi, Matteo

AU - Franciotta, Diego

AU - Rizzo, Roberta

AU - Bellini, Tiziana

AU - Bergamaschi, Roberto

AU - Granieri, Enrico

AU - Fainardi, Enrico

PY - 2015

Y1 - 2015

N2 - Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Natalizumab, a humanized anti-α4 integrin monoclonal antibody, is a highly effective treatment approved for MS. An association between MS and an exposure to Epstein-Barr Virus (EBV) sustained by the levels of antiviral capsid antigen (VCA) and anti-Epstein-Barr nuclear antigen-1 (EBNA-1) IgG has been described. Our goal was to verify the utility of EBV-specific IgG as a marker in Natalizumab treated MS. Twenty patients (17 female and 3 male) in treatment with Natalizumab were enrolled. Serum levels of anti-VCA and anti-EBNA-1 IgG were determined and expressed as arbitrary units (AU) before treatment and every three months for 21 months of therapy. Anti-VCA IgG levels were increased at the 15th month (235410 ± 196712 AU) comparing with the 3rd (98146 ± 47145 AU) and the 6th (109866 ± 52270 AU) months of therapy p

AB - Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Natalizumab, a humanized anti-α4 integrin monoclonal antibody, is a highly effective treatment approved for MS. An association between MS and an exposure to Epstein-Barr Virus (EBV) sustained by the levels of antiviral capsid antigen (VCA) and anti-Epstein-Barr nuclear antigen-1 (EBNA-1) IgG has been described. Our goal was to verify the utility of EBV-specific IgG as a marker in Natalizumab treated MS. Twenty patients (17 female and 3 male) in treatment with Natalizumab were enrolled. Serum levels of anti-VCA and anti-EBNA-1 IgG were determined and expressed as arbitrary units (AU) before treatment and every three months for 21 months of therapy. Anti-VCA IgG levels were increased at the 15th month (235410 ± 196712 AU) comparing with the 3rd (98146 ± 47145 AU) and the 6th (109866 ± 52270 AU) months of therapy p

UR - http://www.scopus.com/inward/record.url?scp=84935915222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935915222&partnerID=8YFLogxK

U2 - 10.1155/2015/901312

DO - 10.1155/2015/901312

M3 - Article

AN - SCOPUS:84935915222

VL - 2015

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

M1 - 901312

ER -